Similar Search Results

Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation: Impact of Bioavailability on Costs and Outcomes

Mittmann, Nicole; Oh, Paul I.; Walker, Scott E.; … - In: PharmacoEconomics 22 (2004) 10, pp. 671-683

Background: The bioavailability of warfarin is an important factor affecting the achievement of therapeutic … anticoagulation. It is uncertain whether less expensive generic preparations of warfarin would compromise prevention of … strategies using warfarin products with variable bioavailability in patients with a prior stroke or transient ischaemic attack …

Persistent link: https://www.econbiz.de/10005590303

Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis

Dranitsaris, George; Vincent, Mark; Crowther, Mark - In: PharmacoEconomics 24 (2006) 6, pp. 593-607

24 respondents (96%) selected dalteparin over warfarin, with an associated gain of 0.157 QALYs. When the incremental cost … that long-term dalteparin therapy is a sound alternative to warfarin for the prevention of recurrent VTEs in patients with …

Persistent link: https://www.econbiz.de/10005590421

Point-of-Care Testing in Oral Anticoagulant Monitoring: Implications for Patient Management

Sickels, Jennifer; Lafata, Jennifer Elston; Ansell, Jack E. - In: Disease Management and Health Outcomes 6 (1999) 5, pp. 291-301

Capillary whole blood point-of-care instruments for prothrombin time testing have been available for the last 10 years for use both in an office or hospital setting as well as at home by patients for self-monitoring of oral anticoagulant therapy. There are currently 4 types of instruments...

Persistent link: https://www.econbiz.de/10005448928

The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation

Panattoni, Laura; Brown, Paul M.; Te Ao, Braden; … - In: PharmacoEconomics 30 (2012) 11, pp. 1067-1084

Background:Background: A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19&ast;2 (&ast;2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with...

Persistent link: https://www.econbiz.de/10010579443

Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis

Attanasio, Ermanno; Russo, Pierluigi; Carunchio, Gabriella - In: PharmacoEconomics 19 (2001) 1, pp. 57-68

Background: In a recent clinical trial, dermatan sulfate was found to be more effective than unfractionated heparin (UFH), but equally well tolerated, for the prevention of deep vein thrombosis (DVT) after major surgery for cancer. Objective: To perform a cost-effectiveness analysis of dermatan...

Persistent link: https://www.econbiz.de/10005243139

Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients: Modelling Study from the Hospital Perspective in Germ...

Schadlich, Peter K.; Kentsch, Michael; Weber, Manfred; … - In: PharmacoEconomics 24 (2006) 6, pp. 571-591

Objective: To estimate, from the hospital perspective in Germany, the cost effectiveness of the low-molecular-weight heparin (LMWH) subcutaneous enoxaparin sodium 40mg once daily (ENOX) relative to no pharmacological prophylaxis (NPP) and relative to subcutaneous unfractionated heparin (UFH)...

Persistent link: https://www.econbiz.de/10004990355

Measuring the Outcomes and Pharmacoeconomic Consequences of Venous Thromboembolism Prophylaxis in Major Orthopaedic Surgery

Sullivan, Sean D.; Kahn, Susan R.; Davidson, Bruce L.; … - In: PharmacoEconomics 21 (2003) 7, pp. 477-496

Patients who have undergone orthopaedic surgery represent a high-risk group for venous thromboembolism (VTE). Despite the routine prophylactic use of antithrombotic agents, patients still experience thrombotic events that can result in mortality and acute morbidity and, in significant numbers of...

Persistent link: https://www.econbiz.de/10005449088

Cost Effectiveness of Bemiparin Sodium versus Unfractionated Heparin and Oral Anticoagulants in the Acute and Long-Term Treatment of Deep Vein Thrombosis

Gomez-Outes, Antonio; Rocha, Eduardo; … - In: PharmacoEconomics 24 (2006) 1, pp. 81-92

Introduction: Low-molecular-weight heparins (LMWHs) are at least as effective and well tolerated as unfractionated heparin (UFH) in the treatment of deep vein thrombosis (DVT), offering easier administration and obviating the need for anticoagulant monitoring, but have a higher acquisition cost...

Persistent link: https://www.econbiz.de/10005449200

Cost Effectiveness of Dalteparin for Preventing Venous Thromboembolism in Abdominal Surgery

Heerey, Adrienne; Suri, Sanjeev - In: PharmacoEconomics 23 (2005) 9, pp. 927-944

Introduction: Patients undergoing abdominal surgeries face substantial risk of experiencing venous thromboembolic events in the perioperative period. The low-molecular-weight heparin dalteparin sodium is clinically effective in reducing the incidence of venous thromboembolism (VTE) in these...

Persistent link: https://www.econbiz.de/10005404949

The Authors' Reply

Kapoor, Alok; Radhakrishnan, Nila; Smith, Kenneth J. - In: PharmacoEconomics 28 (2010) 9, pp. 782-784

Persistent link: https://www.econbiz.de/10010614307

1
2
3
4
5
6
7
8
9
10
Next
Last